| home | faq | contact us | mailing list |
DHA
A Randomized, Double Blind, Placebo-Controlled Trial of the Effects of Docosahexanoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease
| Status: | Active, Not Recruiting |
| Eligible Population(s): | Alzheimer's Disease |
| GCO Number: | 06-1266 IRB approved through 12/31/2008 |
| Principal Investigator: | Mary Sano, PhD |
| Study Coordinator: | Tessa Lundquist |
The objective of this national research study is to determine whether docosahexaenoic acid (DHA) is able to slow the progression of Alzheimer’s disease.
DHA is the main omega-3 fatty acid in our brain and eyes. It is a nutrient found in algae, fish, and human breast milk. Previous studies suggest that it is the key part of fish oil that protects the brain.
DHA has potential neuroprotectant effects and potential anti-amyloid effects. It is taken up by the brain in preference to other fatty acids. DHA is a safe substance – abundant in the brain. Also, it is a major structural fat in the gray matter of the brain and the retina of the eye. It is also a key component of the heart. Numerous studies confirm that everyone, from infants to adults, benefit from an adequate supply of DHA.
This study is closed to recruitment.